Personalis shareholders are heading toward a special meeting to vote on Tempus AI’s proposed acquisition of the cancer genomics company, a deal first announced on July 20 that would value Personalis at roughly $1.5 billion to $1.7 billion depending on how Tempus’ existing minority stake is counted. Under the terms disclosed in a definitive proxy statement filed with the SEC, Personalis stockholders of record as of October 15, 2026 are entitled to vote at the special meeting, with Tempus offering $16.25 per share, payable in its own common stock, though Tempus retains the option to pay up to half the consideration in cash.
A partnership that predates the buyout
The deal builds on a relationship that goes back to November 2023, when Tempus first invested in Personalis and began commercializing the company’s NeXT Personal MRD test, a liquid-biopsy tool designed to detect minimal residual disease — trace cancer cells left behind after treatment — at higher sensitivity than many existing assays. That earlier investment, now worth an estimated $200 million, is part of why reported deal-value figures vary: strip it out and the net new consideration is closer to $1.5 billion, while folding it in pushes the headline figure toward $1.7 billion.
Why Tempus wants Personalis’ MRD platform
Tempus has built its business on pairing AI models with large libraries of clinical and molecular data, and it has positioned minimal residual disease monitoring as a growth area where better data and better algorithms can meaningfully change how oncologists track patients after treatment. Personalis brings a validated, already-commercialized MRD test and an existing base of oncology customers, rather than a platform Tempus would need to build from scratch. Personalis reported preliminary second-quarter revenue of $22.4 million, up 30% year over year, a growth rate that likely factored into Tempus’ willingness to pay a premium — the offer represents roughly a 6% premium over Personalis’ share price the Friday before the announcement.
The vote, the holdouts, and the math
Completing the merger requires approval from holders of a majority of Personalis’ outstanding common stock, a bar that depends heavily on turnout among the company’s dispersed shareholder base. Merck, which holds roughly 13% of Personalis’ voting power through a prior collaboration, has already signed a voting agreement committing its shares in favor of the deal — a meaningful head start toward the majority threshold. Personalis’ board has unanimously recommended that stockholders vote for the merger. Still, at least one law firm, Ademi LLP, has publicly said it is investigating whether Personalis is securing a fair price for shareholders, the kind of inquiry that frequently follows announced mergers and does not by itself indicate wrongdoing, but can sometimes precede shareholder litigation that delays closing.
What could still derail it
The merger agreement includes a protection for Personalis: if Tempus’ share price falls below $46 before closing, Personalis has the right to walk away from the deal, since the all-stock structure means a falling Tempus stock price directly erodes the value Personalis shareholders would actually receive. Tempus shares fell about 8% on the day the deal was announced, closing at $48.41, leaving a relatively thin cushion above that walk-away threshold. The deal also still needs standard antitrust and regulatory clearance, and Tempus and Personalis have said they expect closing in late 2026 or early 2027 — a timeline that assumes no major regulatory objections and a successful shareholder vote.
Two views on consolidation in AI-driven diagnostics
Supporters of the deal argue that combining Tempus’ AI infrastructure and clinical data reach with Personalis’ validated genomic testing creates a stronger, more scalable MRD offering than either company could deliver alone, potentially accelerating how quickly oncologists get actionable residual-disease data back on patients. Critics, including some shareholder-rights attorneys now examining the transaction, question whether a 5-6% premium adequately reflects Personalis’ growth trajectory, especially with second-quarter revenue up 30% year over year, and whether smaller shareholders have enough leverage in a vote already tilted by Merck’s committed 13% stake.
What’s next
The immediate milestone is the special shareholder meeting, where Personalis investors will cast votes based on their October 15 record-date holdings; a result confirming majority approval would clear one of the two major remaining hurdles, alongside regulatory sign-off. Investors and industry watchers tracking the oncology diagnostics space will also be watching Tempus’ share price relative to the $46 walk-away threshold in the weeks ahead, since continued softness there could complicate or reprice the transaction even after a successful vote.
Photo: Tima Miroshnichenko / PEXELS via Pexels
